U.S. markets closed

Eli Lilly and Company (LLY)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
244.15+5.66 (+2.37%)
At close: 4:02PM EDT
Sign in to post a message.
  • L
    Leo
    Hello I really want to invest in Eli Lilly I have done research and I really like the pipeline of drugs. What do you think is a good starting price ?
  • O
    O-Behave
    $BIIB conversation
    $LLY news is GREAT news for $BIIB not bad news. The smoke will clear and we will be heading right back to the $400s

    Hedgefunds are loading here. I guarantee it.

    $BIIB: Cowen Upgrades To Outperform PT $450

    Atlantic Equities Upgrades to Neutral - PT $415

    Citigroup Upgrades to Neutral PT $440

    Oppenheimer Raises Target Price To $450 From $325

    Morgan Stanley Raises Target Price To $455 From $343

    Jeffries PT $500

    SEE U AT $600+💸✈📚📈📽
    Bullish
  • B
    BioPharmaInvestor
    About a quarter of patients had brain swelling and 7.6% of pts had small brain bleeds.....If SAVA's 9 month July 29th readout shows a superior safety and cognition benefit, LLY and BIIB will likely take a major hit...Something to ponder going forward.
  • N
    New
    Probably one of the best pharma stock to hold for growth. But will it ever outperform GOOGL or FB or AMZN?
  • G
    Ganlin
    Stay away from this kind of news pop: no value of this news!
  • D
    Diane
    Lilly has been ripping people off for years with high insulin profits. Now that WMT is offering their own discounted drug LLY decides to compete. So it was fine to frisk people but now there is competition so they decided to come clean? Maybe this could be the start of fixing the drug trade.
  • W
    WealthMastersClub1
    $BIIB conversation
    2 largely overlooked biotechs in AD, PD prevention/cure
    BioVie Inc. (BIVI) --- BIVI's NE3107, a selective inhibitor of inflammatory ERK signaling that reduces neuroinflammation. It is an orally administered first-in-class small molecule that inhibits inflammation-driven insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation and insulin resistance play fundamental roles in the development of Alzheimer’s and Parkinson’s Disease, and NE3107 could represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering from Alzheimer’s and 1 million from Parkinson’s. The FDA recently authorized a pivotal US Phase 3 clinical trial for NE3107.

    AC Immune (ACIU) --- Robust and diverse pipeline of nine therapeutic and three diagnostic product candidates has the potential to greatly improve the treatment of a broad spectrum of Alzheimer’s and neurodegenerative diseases. All of the company’s products were discovered utilizing its proprietary SupraAntigen™ and Morphomer™ technology platforms.
    Partners: Eli Lilly, Janssen (a Johnson&Johnson Co.), Genentech (a Roche Co.), Life Molecular Imaging

    $ACIU $BIVI $SAVA $ANVS $LLY $AVXL
  • k
    kastenz
    Lilly's Donanemab, a monoclonal antibody molecule, which I assume is not part of the Prevail acquisition. Prevail's tech was gene therapy if I recall correctly. Donanemab reportedly was trialed on early disease patients and resulted in slowing of progression only, not reversal (as reported for Cassava's cure).
  • O
    Olakay
    Who finds it concerning that a third official has now resigned from the FDA since Biogen's alzheimers drug approval? LLY shot up because of Biogen's drug approval
  • O
    O-Behave
    $BIIB conversation
    BIIB who gave away their shares??! LMFAOOOOO! $LLY just got a fast track designation this has NOTHING on $BIIB. I'm loading these gifts 🎁
  • O
    O-Behave
    $BIIB conversation
    $BIIB this low volume day is BEAUTIFUL! It signifies that all panic sellers are out. Let's build it organically back above $400. $LLY bad news will circulate soon. Add the BEAUTIFUL news regarding $BIIB eye DRUG and we can look forward to those 450+'s
  • b
    bp
    Paid $34. Yahoo!
  • K
    Kevin
    Cassava SAVA much closer to a cure...
  • W
    Winorlose
    Never buy the PEAK
    Bearish
  • J
    Jane
    CPHI, China Pharma Holdings, .72, may be of interest to long-term investors.
  • I
    I T
    I’ve owned LLC for almost 30 years straight. No surprise seeing a 400bp sell off today.
  • A
    Anonymous
    I'm expecting LLY shares to move based on the FDA decision on the competing amyloid-lowering Alzheimer's drug from BIIB. While approval of Aducanumab might cause a few to sell their LLY, in the longer run it would likely be good news for LLY and Donanemab. It would set a very low bar for Donanemab approval, and should the antibody prove to replicate in a pivotal phase 3 trial its benefit of slowing cognitive decline and secondary endpoint biomarkers of disease progression, it would be well positioned to become a megablockbuster drug for LLY.
  • G
    GrandBishop
    Does anyone know if LLY is buying PMN.ca ARFXF ? PMN has the best in Class PMN310 Antibody which uses Aducanumab. Any thoughts?
    Bullish
  • f
    fazolla
    when is the split coming?
  • R
    Rick
    This strong upside is not surprising to me. I have been expecting it and I know there is more to come in the future. Lilly is the best pharma company out there.